

The Indian Hospital Industry – on a healthy track...

The Indian healthcare industry is estimated to be valued at Rs2.8tn in size in FY11, growing at a 5-year CAGR of 13.1% p.a. CARE Research estimates healthcare industry has the potential to almost double to Rs5.0tn over the next five years, implying a CAGR of 12%. This will be mainly driven by rise in per capita spending on healthcare, change in demographic profile, transition in disease profile, increase in health insurance penetration, and fast growing medical tourism market.

According to CARE Research estimates, hospital industry accounts for roughly 70% of total healthcare market. The hospital industry is classified into three segments – namely, primary, secondary and tertiary. The Indian hospital industry can be broadly categorized as 1) highly fragmented in nature due to large presence of unorganized players, 2) capital intensive with long gestation period, 3) positive supply demand fundamentals, 4) favourable government policies and 4) attractive business model for long term investors with project IRR of 15-17%.

Government of India targets to increase the share of public expenditure on health to at least 2.0%-2.5% of GDP by the end of 12th five year plan (FY13-17) from the current level of 1.26% of GDP, which is well below the emerging market average of 3.0%. However, CARE Research believes it would be difficult for the government to achieve the target considering the worsening fiscal deficit scenario. Given limited room for significant increase in public spending and low faith in the public health system, private institutions will be the major beneficiary of the growing healthcare market – says Mr. Divyesh Shah, Team Leader - CARE Research, CARE Ltd.

Solo practice clinics and small nursing homes mostly run by entrepreneur doctors (with < 30 beds) forms more than 90% of private hospitals whereas large corporate hospitals (with 100 or more beds) account for the remaining. The large share of unorganized and unregulated players has impacted quality of healthcare services due to presence of inadequate infrastructure, which has resulted in gross geographical inequities. This in turn has forced people in rural and tier 2/3 cities to travel to metro cities to get the quality healthcare treatment. According to Ms. Revati Kasture, Head - CARE Research, CARE Ltd, "the share of organized large corporate hospital

players is expected to increase in the coming years due to huge imbalance between the demand and supply of quality healthcare services.”

Hospital cash flow from operations are generally found to be negative in the first 2-3 years of operation due to low operating rate and commitment of high fixed costs by hiring doctors, paramedical staff and administrative team and incurring heavy advertisement expenditure. However, as the hospital gains traction by providing quality service and starts operating well above breakeven level, ROCE and ROE improves sharply due to benefit of high operating leverage. As a result of negative cash flow in the initial period of operation and high capital intensive nature of the business, the payback period of a hospital ranges from 8-12 years.

Among the metro cities in India, Chennai ranks the highest with 4.2 beds per 1,000 population whereas Kolkata ranks the lowest with 2.5 beds. In comparison to global average, hospital beds supply in all the metro cities in India is in-line with the world average of 3 beds per 1,000 persons. Based on capacity expansion plans of large corporate hospital players, we note that Mumbai is expected to witness the highest supply of hospital beds during FY12-FY14 with 4,632 beds, followed by Kolkata, Delhi and Chennai.

Contact:

Revati Kasture

Head - CARE Research

revati.kasture@careratings.com

Divyesh Shah

Asst General Manager

divyesh.shah@careratings.com

Utkarsh Nopany

Deputy Manager

utkarsh.nopany@careratings.com

Disclaimer

This report is prepared by CARE Research, a division of Credit Analysis & REsearch Limited [CARE]. CARE Research has taken utmost care to ensure accuracy and objectivity while developing this report based on information available in public domain. However, neither the accuracy nor completeness of information contained in this report is guaranteed. CARE Research operates independently of ratings division and this report does not contain any confidential information obtained by ratings division, which they may have obtained in the regular course of operations. The opinion expressed in this report cannot be compared to the rating assigned to the company within this industry by the ratings division. The opinion expressed is also not a recommendation to buy, sell or hold an instrument.

CARE Research is not responsible for any errors or omissions in analysis/inferences/views or for results obtained from the use of information contained in this report and especially states that CARE (including all divisions) has no financial liability whatsoever to the user of this report. This report is for the information of the intended recipients only and no part of this report may be published or reproduced in any form without prior written permission of CARE Research.

Credit Analysis and Research Limited proposes, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed a draft red herring prospectus (“DRHP”) with the Securities and Exchange Board of India (“SEBI”). The DRHP is available on the website of SEBI at www.sebi.gov.in as well as on the websites of the Book Running Lead Managers at www.investmentbank.kotak.com, www.dspml.com, www.edelcap.com, www.icicisecurities.com, www.idbicapital.com, and www.sbcaps.com. Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled “Risk Factors” of the DRHP.

This press release is not for publication or distribution to persons in the United States, and is not an offer for sale within the United States of any equity shares or any other security of Credit Analysis & Research Ltd. Securities of Credit Analysis & Research Ltd., including its equity shares, may not be offered or sold in the United States absent registration under U.S. securities laws or unless exempt from registration under such laws.